Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (636)
  2. Journal Article (503)
  3. Review (142)
  4. Editorial (64)
  5. Research Letter (50)
  6. Correspondence (14)
  7. Guidelines (6)
  8. Book Section (3)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Department of Medicine (1158)
  2. Graduate Medical Education (1115)
  3. GME, Medicine (1091)
  4. Hematologic Malignancies, Division of (746)
  5. Weinberg Fellows (657)
  6. Solid Tumor Oncology Division (614)

More Groups

People
  1. Jan Bewersdorf (102)
  2. Zachary Epstein-Peterson (93)
  3. Gunjan Shah (91)
  4. Maria Palomba (91)
  5. Gilles Salles (86)
  6. Michael Scordo (85)

More People

Years
  1. 2025 (158)
  2. 2024 (357)
  3. 2023 (296)
  4. 2022 (222)
  5. 2021 (159)
  6. 2020 (114)

More Years

Publications
  1. Blood (287)
  2. Journal of Clinical Oncology (218)
  3. Clinical Cancer Research (38)
  4. Annals of Oncology (35)
  5. Cancer Research (35)
  6. Journal of Thoracic Oncology (30)

More Publications

Publishers
  1. American Society of Hematology (322)
  2. American Society of Clinical Oncology (250)
  3. Elsevier Inc. (142)
  4. Nature Publishing Group (107)
  5. American Association for Cancer Research (104)
  6. Oxford University Press (61)

More Publishers

Results (1422)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS
    Meeting Abstract

    Stein, E. M.; Boussi, L.; Mims, A.; Watts, J. M.; Mannis, G. N.; Liu, H.; Sallman, D.; Ravandi, F.; Schiller, G. J.; Wang, E. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase II study of the menin inhibitor revumenib in leukemia associated with upregulation of HOX genes: Trial in progress
    Meeting Abstract

    Issa, G. C.; Chin, K. K.; Blachly, J. S.; Farhat, A.; Xiao, L.; Ning, J.; Cuglievan, B.; Shukla, N.; Sasaki, K.; Loghavi, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save